Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug

1. Gan & Lee Pharmaceuticals: A Beijing-based Chinese biotech company that has released mid-stage data for its homegrown obesity drug.
2. Mid-Stage Data: The company has unveiled the results of its Phase 2b clinical trial, which showed competitive weight loss data for its GLP-1 drug.
3. Clinical Trial: The randomized study was conducted across clinical trial centers in China and enrolled 340 adults who were obese (BMI ≥ 28) or overweight (BMI ≥ 24).
4. Weight Loss: The drug has shown promising results in weight loss, which could potentially compete with global pharma heavyweights like Novo Nordisk and Eli Lilly.
5. GLP-1 Drug: The drug is a GLP-1 (glucagon-like peptide-1) receptor agonist, which is a class of medications commonly used for weight loss and diabetes treatment.